Understand the difference between biosimilars and generics, how they impact medication costs, and if it's safe to switch your biologic therapy.
2
Explore the 2026-2030 patent cliff for biologic drugs. Learn how emerging biosimilars for Keytruda and Eylea will impact healthcare costs, FDA regulations, and patient access.
10
Biosimilars are not generics-they're highly similar versions of complex biologic drugs. Clinical evidence from hundreds of thousands of patients confirms they work just as well as the originals, with no meaningful difference in safety or effectiveness.
12
